


Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

Listing of Claims

Claim 1-12. (Cancelled)

Claim 13. (Currently Amended) A compound of formula (I')



~~the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms~~ or an N-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof wherein

R¹ and R² each independently represents hydrogen, C₁₋₄alkyl, NR⁹R¹⁰, C₁₋₄alkyloxy or Het³-O-C₁₋₄alkyl; or

R¹ and R² taken together with the carbon atom with which they are attached from a C₃₋₆cycloalkyl;

R⁴ represents hydrogen, C₁₋₄alkyl, or C₂₋₄alkenyl;

U represents C₁₋₄alkyloxy, phenyl, halo, oxo, carbonyl or hydroxyl;

R⁵ and R⁶ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C₁₋₄alkyl, and C₁₋₄alkyloxy or R⁵ and R⁶ each independently represent C₁₋₄alkyl substituted with phenyl;

R⁷ and R⁸ are each independently selected from hydrogen or C₁₋₄alkyl;

R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl or C₁₋₄alkyloxycarbonyl;

R¹¹ and R¹² are each independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, nitro, Het⁴, phenyl, phenyloxy, C₁₋₄alkyloxycarbonyl, hydroxycarbonyl, NR⁵R⁶, C₁₋₄alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het² and NR⁷R⁸, C₂₋₄alkenyl substituted with one substituent selected from phenyl-C₁₋₄alkyl-oxycarbonyl, C₁₋₄alkyloxycarbonyl, hydroxycarbonyl, Het⁵-carbonyl, and C₁₋₄alkyl substituted with one or where possible two or three substituents each independently selected from halo, dimethylamine, trimethylamine, amine, cyano, Het⁶, Het⁷-carbonyl, C₁₋₄alkyloxycarbonyl or hydroxycarbonyl;

Het⁴ ~~represents a heterocycle selected from pyridinyl, piperidinyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;~~

Het² represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said Het² optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;

Het³ represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het⁴ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl, triazolyl, tetrazolyl or morpholinyl, said Het⁴ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;

Het⁵ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁵ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy;

Het⁶ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁶ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy; and
Het⁷ represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het⁷ optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C₁₋₄alkyl or C₁₋₄alkyloxy.

Claim 14-22. (Cancelled)

Claim 23. (Previously presented) A compound according to claim 13, wherein R¹ and R² each independently represents hydrogen, C₁₋₄alkyl, or C₁₋₄alkyloxy.

Claim 24. (Previously presented) A compound according to claim 13, wherein R¹ and R² each independently represents methyl or methoxy.

Claim 25. (Previously presented) A compound according to claim 13, wherein R¹ and R² taken together with the carbon atom with which they are attached form cyclopropyl or cyclobutyl.

Claim 26. (Previously presented) A compound according to claim 13, wherein R⁴ represents hydrogen.

Claim 27. (Previously presented) A compound according to claim 13, wherein U represents hydroxy or halo.

Claim 28. (Currently Amended) A compound according to claim 13, wherein Het⁵ represents a monocyclic heterocycle selected from piperazinyl or morpholinyl;

Claim 29. (Previously presented) A compound according to claim 13, wherein Het⁷ represents a monocyclic heterocycle selected from piperazinyl or morpholinyl.

Claim 30. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 13.

Claim 31. (Cancelled)

Claim 32. (Currently Amended) A compound according to claim 13, wherein the compound is selected from:

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;
 (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methyl-benzeneacetamide;
 (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methoxy-benzeneacetamide;
 (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-hydroxy-benzeneacetamide;
 (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3,5-dimethyl-benzeneacetamide);
~~(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)-3-(phenylmethoxy)benzeneacetamide;~~
 (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-(carboxymethoxy)-benzeneacetamide;
 (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;
 (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-fluorotricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;
 (1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-methoxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;
 (1 α ,2 α ,3 β ,5 β ,7 β)-N-(5-methoxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;
 3-(3-{2-[(5-fluoro-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoic acid; and
 4-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)butanoic acid; ~~and~~

~~tert-butyl 4-[3-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoyl]-1,4-diazepane-1-carboxylate~~; or a N-oxide, a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof.


Claim 33. (New) A compound according to claim 13 wherein the compound is selected from

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-benzeneacetamide;

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methyl-benzeneacetamide; and

(1 α ,2 β ,3 β ,5 β ,7 β)-N-(5-hydroxytricyclo[3.3.1.1^{3,7}]dec-2-yl)- α , α -dimethyl-3-methoxy-benzeneacetamide; or a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

Claim 34. (New) A compound according to claim 13 wherein the compound is



or a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

Claim 35. (New) A compound according to claim 13 wherein R¹ and R² each represent C₁₋₄alkyl.